Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 62 Shanghai 52 Guangzhou 39 Hangzhou 20 Changsha 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines6 Innolake Biopharm2 Minghui Pharmaceutical (Hangzhou) Ltd2 Eli Lilly and Company2 MediLink Therapeutics (Suzhou) Co., Ltd.2
Site location
Beijing62 Shanghai52 Guangzhou39 Hangzhou20 Changsha18
All 67 locations
Target enrolment
to

Trials with a site in Shanghai

52 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
348
Shanghai
2026-11
Recruiting
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
52
Shanghai
2026-06-16
Not yet open
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Recruiting
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
A Study of PLB-002 in Advanced Solid Tumors
NCT07304128Advanced Solid Tumor
Primelink BioTherapeitics(ShenZhen) Limited
Phase 1
100
Shanghai
2026-02-06
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
198
Shanghai
2026-01-07
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
444
Shanghai
2025-10-24
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
LaNova Medicines Limited
Phase 1/2
320
Shanghai
2025-09-17
Recruiting
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Recruiting
Hansoh BioMedical R&D Company
Phase 1
502
Shanghai
2025-05-29
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Active, closed
Daiichi Sankyo
Phase 2
335
Changsha, Shanghai
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
Innolake Biopharm
Phase 1
240
Shanghai
2024-10-30
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Beijing, Guangzhou, Shanghai
2024-07-01
Recruiting
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
DrugMHB039A
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Ruijin Hospital
Early Phase 1
34
Shanghai
2023-12-20
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
DrugMHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Active, closed
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
30
Shanghai
2023-04-01
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Active, closed
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
Active, closed
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
Recruiting
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
Shanghai Hansoh Biomedical Co., Ltd
Phase 1
177
Shanghai
2022-01-05
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

41 of the 52 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 52 studies
PhaseStudiesRecruitingShare
Phase 1312659.6%
Phase 1/2181334.6%
Early Phase 1223.8%
Phase 2101.9%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
BeOne Medicines66
Eli Lilly and Company21
Hansoh BioMedical R&D Company22
Innolake Biopharm21
MediLink Therapeutics (Suzhou) Co., Ltd.22
Minghui Pharmaceutical (Hangzhou) Ltd20
Shanghai East Hospital21
Ascentage Pharma Group Inc.11
Axter Therapeutics (Beijing) Co., Ltd11
Beijing Biostar Pharmaceuticals Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.